GlassScriptPhysician profile
James Conner Lockwood
NPI 1366838120
$5,060.46
in general payments reported to CMS, 2019-2025
19 companies · $950 in 2025
The $950 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $149 · 2021: $925 · 2022: $975 · 2023: $1,074 · 2024: $754 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,836.60 | 2019-2025 | Clareon, Unity, Wavelight Ex500 Excimer Laser |
| Glaukos Corporation | $575.15 | 2020-2025 | Idosetr, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Notal Vision, INC. | $335.94 | 2022 | |
| Kala Pharmaceuticals, INC. | $329.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $256.55 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $241.03 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $232.52 | 2019-2024 | Cequa |
| Oyster Point Pharma, INC. | $201.48 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $191.58 | 2022-2025 | Miebo, Vyzulta |
| Harrow Eye, LLC | $180.67 | 2024 | Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $144.93 | 2023 | Tecnis Iol, Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $118.18 | 2021 | |
| New World Medical,INC. | $112.71 | 2022-2023 | |
| Abbvie INC. | $112.35 | 2024-2025 | |
| Allergan, INC. | $58.96 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $52.83 | 2025 | Acthar |
| Thea Pharma INC. | $38.65 | 2023-2025 | Iyuzeh |
| Amgen INC. | $24.98 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $15.98 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lockwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.